| Literature DB >> 22198501 |
Mikael Ebbo1, Laurent Daniel, Michel Pavic, Pascal Sève, Mohamed Hamidou, Emmanuel Andres, Stéphane Burtey, Laurent Chiche, Jacques Serratrice, Maïté Longy-Boursier, Marc Ruivard, Julien Haroche, Bertrand Godeau, Anne-Bérengère Beucher, Jean-Marie Berthelot, Thomas Papo, Jean-Loup Pennaforte, Audrey Benyamine, Noémie Jourde, Cédric Landron, Pascal Roblot, Olivier Moranne, Christine Silvain, Brigitte Granel, Fanny Bernard, Veronique Veit, Karin Mazodier, Emmanuelle Bernit, Hugues Rousset, José Boucraut, Jean-Jacques Boffa, Pierre-Jean Weiller, Gilles Kaplanski, Pierre Aucouturier, Jean-Robert Harlé, Nicolas Schleinitz.
Abstract
IgG4-related systemic disease is now recognized as a systemic disease that may affect various organs. The diagnosis is usually made in patients who present with elevated IgG4 in serum and tissue infiltration of diseased organs by numerous IgG4+ plasma cells, in the absence of validated diagnosis criteria. We report the clinical, laboratory, and histologic characteristics of 25 patients from a French nationwide cohort. We also report the treatment outcome and show that despite the efficacy of corticosteroids, a second-line treatment is frequently necessary. The clinical findings in our patients are not different from the results of previous reports from Eastern countries. Our laboratory and histologic findings, however, suggest, at least in some patients, a more broad polyclonal B cell activation than the skewed IgG4 switch previously reported. These observations strongly suggest the implication of a T-cell dependent B-cell polyclonal activation in IgG4-related systemic disease, probably at least in part under the control of T helper follicular cells.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22198501 DOI: 10.1097/MD.0b013e3182433d77
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889